EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY-NC 4.0

Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol

He Zhao, Xiaowu Zhang, Pengfei Tian, Yingen Luo, Wei Sun, Ying Li, Jingui Li, Tao Gong, Zhengqiang Yang, Peng Song, Xiao Li iD

BMJ Open · 2024

DOI: 10.1136/bmjopen-2023-080805 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BMJ Open, 2024. Verfasst von He Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences a…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Hepatic Artery, Infusions, Intra-Arterial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CAMS Initiative for Innovative Medicine, National Natural Science Fund of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction The exact role of hepatic arterial infusion chemotherapy (HAIC) in advanced hepatocellular carcinoma (aHCC) is still unknown. The combination of HAIC and sorafenib has been proven to be more effective than sorafenib alone in the first-line treatment of aHCC. The aim of the study is to evaluate the efficacy and safety of HAIC plus regorafenib in the second-line treatment of aHCC. Methods and analysis This is a multicenter, open-label, randomised controlled phase III trial. A total of 294 patients with aHCC, who are unable to tolerate the first-line systemic therapy or progress after the first-line systemic therapy, will be enrolled in the study. The patients will be randomly (2:1) assigned into the combination treatment group (HAIC plus regorafenib, n=196) and the control group (regorafenib alone, n=98). HAIC and regorafenib (160 mg/day) will be given in a 4-week cycle. The primary endpoint is overall survival in the intention-to-treat population. The second endpoints include progression-free survival, overall response rate, time to progression, etc. The radiological assessments will be based on the criteria of Response Evaluation Criteria in Solid Tumors 1.1. Ethics and dissemination This study is approved by the ethics committee of Cancer Hospital, Chinese Academy of Medical Sciences. All participants are required to provide written informed consent. The results of this study will be disseminated through peer-reviewed publications and esteemed academic conferences. Trial registration number Chinese Clinical Trial Registry (ChiCTR2300073075).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularHepatic ArteryInfusions, Intra-ArterialLiver NeoplasmsPhenylurea CompoundsPyridinesAdultAgedFemaleHumansMaleMiddle AgedAntineoplastic AgentsClinical Trials, Phase III as TopicMulticenter Studies as TopicRandomized Controlled Trials as TopicSorafenib

Stichwörter der Autor:innen

CHEMOTHERAPYHepatobiliary tumoursInterventional radiologyRandomized Controlled Trial

Substanzen

Antineoplastic AgentsPhenylurea CompoundsPyridinesregorafenibSorafenib

Autor:innen und Institutionen

  • Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shen…
  • Department of Interventional Therapy, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
  • Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China songpeng@cicams-sz.org…
  • Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang, Hebei, China.

ORCID-Profile: Xiao Li

Förderung

  • CAMS Initiative for Innovative Medicine
  • National Natural Science Fund of China

Zitieren

APA

Zhao, H., Zhang, X., Tian, P., Luo, Y., Sun, W., Li, Y., Li, J., Gong, T., Yang, Z., Song, P., & Li, X. (2024). Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol. BMJ Open. https://doi.org/10.1136/bmjopen-2023-080805

Vancouver

Zhao H, Zhang X, Tian P, Luo Y, Sun W, Li Y, et al. Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol. BMJ Open. 2024. doi:10.1136/bmjopen-2023-080805

BibTeX
@article{Zhao2024,
  author = {Zhao, He and Zhang, Xiaowu and Tian, Pengfei and Luo, Yingen and Sun, Wei and Li, Ying and Li, Jingui and Gong, Tao and Yang, Zhengqiang and Song, Peng and Li, Xiao},
  title = {Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol},
  journal = {BMJ Open},
  year = {2024},
  doi = {10.1136/bmjopen-2023-080805}
}
Kostenlos starten →